Page last updated: 2024-12-10

phosphothreonine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Phosphothreonine: The phosphoric acid ester of threonine. Used as an identifier in the analysis of peptides, proteins, and enzymes. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

O-phospho-L-threonine : A L-threonine derivative phosphorylated at the side-chain hydroxy function. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID3246323
CHEBI ID37525
SCHEMBL ID42675
MeSH IDM0016736

Synonyms (41)

Synonym
threonine phosphate
einecs 214-217-5
unii-3l4wx7b1ei
3l4wx7b1ei ,
l-threonine, dihydrogen phosphate (ester)
threoninium dihydrogen phosphate
CHEBI:37525
o3-phosphothreonine
(2s,3r)-2-amino-3-hydroxybutanoic acid 3-phosphate
o-phosphono-l-threonine
threonine phosphate ester
1114-81-4
l-threonine phosphate
o-phospho-l-threonine
l-threonine o-3-phosphate
phosphothreonine
(2s,3r)-2-amino-3-phosphonooxybutanoic acid
AKOS006237893
(2s,3r)-2-amino-3-(phosphonooxy)butanoic acid
l-threonine o-phosphate
SCHEMBL42675
threonine phosphate [who-dd]
treonin fosfatum
phospho-l-threonine
l-threonine, o-phosphono-
l-o-phosphothreonine
l-phosphothreonine
threonine, phosphate
threonine, di-h phosphate
o-phosphothreonine
J-002589
l-2-amino-3-hydroxybutanoic acid 3-phosphate
USRGIUJOYOXOQJ-GBXIJSLDSA-N
mfcd00069578
synonyms sources
h-thr(po3h2)-oh
rel-(2s,3r)-2-amino-3-(phosphonooxy)butanoic acid
Q21099038
(2s,3r)-2-amino-3-(phosphonooxy)butanoicacid
CS-0059358
HY-113014

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" The pharmacokinetic behaviour of the various active ingredients was examined at a haematic level."( Pharmacokinetic study of the relative bioavailability and bioequivalence after oral intensive or repeated short term treatment with two polyamino acid formulations.
Castana, R; Insirello, L; Leonardi, G; Matera, M, 1993
)
0.29

Bioavailability

ExcerptReferenceRelevance
" Likely arachidonic acid reducing NO bioavailability through all these mechanisms could potentiate its platelet aggregating power."( The arachidonic acid effect on platelet nitric oxide level.
Leoncini, G; Segantin, A; Signorello, MG, 2009
)
0.35

Dosage Studied

ExcerptRelevanceReference
" Phosphorylation of pp105 followed the dose-response characteristics of the IGF-I receptor."( An altered IGF-I receptor is present in human leukemic cells.
Ermel, B; Häring, HU; Kellerer, M; Obermaier-Kusser, B; Petrides, PE; Wallner, U, 1990
)
0.28
" Dose-response curves in myometrial cells expressing the endogenous OTR indicated a significant effect of OT on eukaryotic elongation factor 2 dephosphorylation at 1 nM, a concentration close to the dissociation constant (K(d)) of OT."( Oxytocin induces dephosphorylation of eukaryotic elongation factor 2 in human myometrial cells.
Carrier, ME; Devost, D; Girotti, M; Russo, C; Zingg, HH, 2005
)
0.33
" elegans specific dosage complex can be phosphorylated on most subunits, suggesting its regulation by kinases."( Caenorhabditis elegans has a phosphoproteome atypical for metazoans that is enriched in developmental and sex determination proteins.
Gnad, F; Jedrusik-Bode, M; Mann, M; Wiśniewski, JR; Zielinska, DF, 2009
)
0.35
" A dose-response cell proliferation assay showed that low doses of ND-MWCNT (1."( Effects of nitrogen-doped multi-walled carbon nanotubes compared to pristine multi-walled carbon nanotubes on human small airway epithelial cells.
Castranova, V; Cruz-Silva, R; Ding, W; Endo, M; McLoughlin, C; Mihalchik, AL; Porter, DW; Qian, Y; Schwegler-Berry, D; Sisler, JD; Snyder-Talkington, BN; Stefaniak, AB; Terrones, M; Tsuruoka, S, 2015
)
0.42
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
Escherichia coli metaboliteAny bacterial metabolite produced during a metabolic reaction in Escherichia coli.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
O-phosphoamino acid
L-threonine derivativeA proteinogenic amino acid derivative resulting from reaction of L-threonine at the amino group or the carboxy group, or from the replacement of any hydrogen of L-threonine by a heteroatom.
non-proteinogenic L-alpha-amino acidAny L-alpha-amino acid which is not a member of the group of 23 proteinogenic amino acids.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (1,207)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990149 (12.34)18.7374
1990's361 (29.91)18.2507
2000's414 (34.30)29.6817
2010's247 (20.46)24.3611
2020's36 (2.98)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 31.25

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index31.25 (24.57)
Research Supply Index7.10 (2.92)
Research Growth Index4.69 (4.65)
Search Engine Demand Index43.69 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (31.25)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews34 (2.79%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other1,183 (97.21%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]